![Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI](https://cedclinic.com/wp-content/uploads/2026/06/ced-pexels-4226264-1-150x150.jpg "Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI 12")
France’s Medical Cannabis Trial: 3% Serious Adverse Events in 3,164 Patients Over Three Years
During the experimentation, 3% of patients treated with MC experienced at least one serious ADR. The safety profile was dominated by neurological, gastrointestinal, and psychiatric ADRs. Only one case of MC misuse was identified with inflorescences. This…
Association of Multimodal Cannabis Use with Adverse Events among Adolescents and Young Adults.
The ways cannabis is consumed, or modes of use, have increased and diversified in recent years, especially among young people. Associations of multimodal can...
CBD Gummies Hallucinations: What the Evidence Actually Shows
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic CbdProduct SafetyAdverse EventsDrug…
Canada’s Cannabis Safety Surveillance System: What Six Years of Adverse Reaction Reports Reveal
Overall, individuals reporting an adverse reaction to a cannabis product (n=698) were 56.0 ± 20.0 years of age. 45.4% of reporting individuals were female, and 67.5% of individuals self-reported using cannabis for medical purposes... Most cases were…
New funding will allow a Colorado research institute to track psychedelic use
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic PsychedelicsPatient SafetyClinical…
These 5 N.J. smoke shops were just ordered to shut down in city’s cannabis crackdown
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Patient SafetyProduct…
Cannabis Medicines Appear Broadly Tolerated in Adults Over 50, But Key Uncertainties Remain
Although cannabinoid-based medications were generally safe and acceptable to adults aged over 50 years, these estimates are limited by the lack of a control condition and considerable heterogeneity. Nevertheless, they complement and are consistent with…
Cannabis Medicines Cause Dose-Dependent Side Effects in Older Adults, Meta-Analysis Finds
THC dose-dependently increased the incidence of dry mouth, dizziness/lightheadedness, mobility/balance/coordination difficulties, dissociative/thinking/perception problems and somnolence/drowsiness.
Investigating the effectiveness and adverse events of medicinal cannabis for patients with muscle spasticity or spasms.
Appropriate treatment of muscle spasticity and spasms is important as these conditions may significantly impair patients' quality of life. Conventional pharm...
Medical Cannabis Use in France: An Observational Safety Study Based on the RECANN Registry and the Pharmacovigilance/Addictovigilance System From 2021 to 2024.
The French National Agency for Medicines and Health Products Safety implemented in 2021 a nationwide experimentation for medical cannabis (MC), designed to a...